P manufactures Contrave®, a drug that treats obesity. P manufactures Contrave®, a drug that treats obesity. McKesson and MPRS are legally distinct entities. On June 9, 2016, P entered into the Distribution Agreement with McKesson, which contemplated that McKesson would purchase and distribute Contrave® to various pharmacies in the United States. McKesson had certain rights, including a right to set off debts owed between P and its affiliates against debts owed between McKesson and its affiliates. As of the petition date, McKesson owed P $6,932,816.40. On July 15, 2016, Pr entered into the Services Agreement with MPRS. The Services Agreement does not incorporate or relate to the Distribution Agreement; they are wholly distinct. As of the petition date, P owed MPRS approximately $9,100,000. On March 12, 2018, P filed Chapter 11. P, McKesson, and MPRS entered into three stipulations and presented their motion to the court. The Court entered an order approving a stipulation between the P and MPRS. P would pay MPRS the sum of $6,027,155 on account of the post-petition reimbursements MPRS remitted under the LoyaltyScript® program. P would make weekly payments of $1,675,000 to MPRS. None of the payments would apply to MPRS's prepetition claim of approximately $9,100,000. Before the court is McKesson’s set off motion.

This section contains the nature of the case and procedural background.

The legal issues presented in this case will be displayed here.

The court's holding and decision will be displayed here.

Legal analysis from Dean's Law Dictionary will be displayed here.